Suppression of pancreatic cancer by the dominant negative ras mutant, N116Y

Journal of Surgical Research

Volumn 66, Issue 2, 1996, Pages 125-130

  Shichinohe, Toshiaki ^a   Senmaru, Naoto ^a   Furuuchi, Keiji ^a   Ogiso, Yoshifumi ^a   Ishikura, Hiroshi ^a   Yoshiki, Takashi ^a   Takahashi, Toshiyuki ^a   Kato, Hiroyuki ^a   Kuzumaki, Noboru ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CARCINOGENICITY; CONTROLLED STUDY; GENE MUTATION; GENE THERAPY; GROWTH INHIBITION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUDE MOUSE; ONCOGENE H RAS; ONCOGENE K RAS; PANCREAS CANCER; PHENOTYPE; PRIORITY JOURNAL;

EID: 0030498918     PISSN: 00224804     EISSN: None     Source Type: Journal    
DOI: 10.1006/jsre.1996.0383     Document Type: Article

References (28)

1. 1. Warshaw, A. L., and Fernández-del Castillo, C. Pancreatic carcinoma. N. Engl. J. Med. 326: 455, 1992.
2. 2. Cameron, J. L., Crist, D. W., Sitzmann, J. V., Hruban, R. H., Boitnott, J. K., Seidler, A. J., and Coleman, J. Factors influencing survival after pancreaticoduodenectomy for pancreatic cancer. Am. J. Surg. 161: 120, 1991.
3. 3. Arbuck, S. G. Overview of chemotherapy for pancreatic cancer. Int. J. Pancreatol. 7: 209, 1990.
4. 4. Almoguera, C., Shibata, D., Forrester, K., Martin, J., Arnheim, N., and Perucho, M. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 53: 549, 1988.
5. 5. Grünewald, K., Lyons, J., Fröhlich, A., Feichtinger, H., Weger, R. A., Schwab, G., Janssen, J. W. G., and Bartram, C. R. High frequency of Ki-ras codon 12 mutations in pancreatic adenocarcinomas. Int. J. Cancer 43: 1037, 1989.
6. 6. Pellegata, N. S., Sessa, F., Renault, B., Bonato, M., Leone, B. E., Solcia, E., and Ranzani, G. N. K-ras and p53 gene mutations in pancreatic cancer: Ductal and nonductal tumors progress through different genetic lesions. Cancer Res. 54: 1556, 1994.
7. 7. Redston, M. S., Caldas, C., Seymour, A. B., Hruban, R. H., da Costa, L., Yeo, C. J., and Kern, S. E. p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions. Cancer Res. 54: 3025, 1994.
8. 8. Yanagisawa, A., Ohtake, K., Ohashi, K., Hori, M., Kitagawa, T., Sugano, H., and Kato, Y. Frequent c-Ki-ras oncogene activation in mucous cell hyperplasias of pancreas suffering from chronic inflammation. Cancer Res. 53: 953, 1993.
9. 9. Ogiso, Y., Yokoyama, T., Watari, H., Shih, T. Y., and Kuzumaki, N. Resistance of NIH3T3 cells to v-fes transformation induced by a dominant negative H-ras mutant. Exp. Cell. Res. 208: 415, 1993.
10. 10. Ogiso, Y., Sakai, N., Watari, H., Yokoyama, T., and Kuzumaki, N. Suppression of various human tumor cell lines by a dominant negative H-ras mutant. Gene Therapy 1: 403, 1994.
11. 11. Sakai, N., Ogiso, Y., Fujita, H., Watari, H., Koike, T., and Kuzumaki, N. Induction of apoptosis by a dominant negative H-RAS mutant (116Y) in K562 cells. Exp. Cell. Res. 215: 131, 1994.
12. 12. Trahey, M., and McCormick, F. A cytoplasmic protein stimulates normal N-ras p21 GTPase, but does not affect oncogenic mutants. Science 238: 542, 1987.
13. 13. Gibbs, J. B., Schaber, M. D., Allard, W. J., Sigal, I. S., and Scolnick, E. M. Purification of ras GTPase activating protein from bovine brain. Proc. Natl. Acad. Sci. USA 85: 5026, 1988.
14. 14. Takahashi, T., Ishikura, H., Iwai, K, Takahashi, C., Kato, H., Tanabe, T., and Yoshiki, T. Cytokine regulation of cell-to-cell interactions in lymphokine-activated killer cell cytotoxicity in vitro. Cancer Immunol. Immunother. 36: 76, 1993.
15. 15. Iwai, K., Ishikura, H., Kaji, M., Sugiura, H., Ishizu, A., Takahashi, C., Kato, H., Tanabe, T., and Yoshiki, T. Importance of E-selectin (ELAM-1) and sialyl Lewis(a) in the adhesion of pancreatic carcinoma cells to activated endothelium. Int. J. Cancer 54: 972, 1993.
16. 16. Sugiura, H., Ishikura, H., Omi, M., Kaji, M., Iwai, K., Kishimoto, T., Takahashi, T., Kimura, C., Kato, H., and Yoshiki, T. Lymphokine-activated killer cytotoxicity against pancreas adenocarcinoma cell lines and vascular endothelial cells. Pathol. Int. 44: 688, 1994.
17. 17. Kaji, M., Ishikura, H., Kishimoto, T., Omi, M., Ishizu, A., Kimura, C., Takahashi, T., Kato, H., and Yoshiki, T. E-selectin expression induced by pancreas-carcinoma-derived interleukin-1 alpha results in enhanced adhesion of pancreas-carcinoma cells to endothelial cells. Int. J. Cancer 60: 712, 1995.
18. 18. Clanton, D. J., Hattori, S., and Shih, T. Y. Mutations of the ras gene product p21 that abolish guanine nucleotide binding. Proc. Natl. Acad. Sci. USA 83: 5076, 1986.
19. 19. Feigner, P. L., Gadek, T. R., Holm, M., Roman, R., Chan, H. W., Wenz, M., Northrop, J. P., Ringold, G. M., and Danielsen, M. Lipofection: A highly efficient, lipid-mediated DNA-transfection procedure. Proc. Natl. Acad. Sci. USA 84: 7413, 1987.
20. 20. Innis, M. A., Gelfand, D. H., Sninsky, J. J., and White, T. J. PCR Protocols. San Diego, CA: Academic Press, 1990. Pp. 14-15.
21. 21. Ogiso, Y., Hwang, Y. W., Shih, T. Y., and Kuzumaki, N. Biological activity of a K-ras mutant that contains the 12R/59T/116Y mutations. Cancer Lett. 75: 19, 1993.
22. 22. Hwang, Y. W., Zhong, J. M., Poullet, P., and Parmeggiani, A. Inhibition of SDC25 C-domain-induced guanine-nucleotide exchange by guanine ring binding domain mutants of v-H-ras. J. Biol. Chem. 268: 24692, 1993.
23. 23. Carter, G., Gilbert, C., and Lemoine, N. R. Effects of antisense oligonucleotides targeting K-ras expression in pancreatic cancer cell lines. Int. J. Oncol. 6: 1105, 1995.
24. 24. Kohl, N. E., Mosser, S. D., deSolms, S. J., Guiliani, E. A., Pompliano, D. L., Graham, S. L., Smith, R. L., Scolnick, E. M., Oliff, A., and Gibbs, J. B. Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor. Science 260: 1934, 1993.
25. 25. Shirasawa, S., Furuse, M., Yokoyama, N., and Sasazuki, T. Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. Science 260: 85, 1993.
26. 26. Yokoyama, T. Inhibition of RAS-dependent transformation by using dominant negative RAS mutant N116Y. Hokkaido J. Med. Sci. 70: 459, 1995.
27. 27. DiMaio, J. M., Clary, B. M., Via, D. F., Coveney, E., Pappas, T. N., and Lyerly, H. K. Directed enzyme pro-drug gene therapy for pancreatic cancer in vivo. Surgery 116: 205, 1994.
28. 28. Osaki, T., Tanio, Y., Tachibana, I., Hosoe, S., Kumagai, T., Kawase, I., Oikawa, S., and Kishimoto, T. Gene therapy for carcinoembryonic antigen-producing human lung cancer cells by cell type-specific expression of herpes simplex virus thymidine kinase gene. Cancer Res. 54: 5258, 1994.